NETRIS Pharma will attend the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. For this occasion, NETRIS Pharma will present the preclinical characteristics of NP137, its first-in-class humanized anti-Netrin-1 antibody, currently in preclinical development. NP137 exhibits anti-tumor activity by inducing dependence receptors-mediated cell death. A clinical trial is planned at the end of 2015, in collaboration with EORTC. This work is supported by the FP7 Hermione-2-Man grant from European Union.